Solvey-Pharm

2010: Renaming into Abbott Prodakts

Announced Solvey Pharm LLC change of the name of the company since 4/1/2010. New name of the company: Ebbott Prodakts (Abbott Prodakts LLC) limited liability company.

2009: The company is sold to Abbott Laboratories for 4.8 billion euros

In September, 2009 it became known that the American company Abbott Laboratories signed the agreement on acquisition of a pharmapodrazdeleniye of the Belgian chemical and pharmaceutical conglomerate Solvay SA. Transaction amount is about 4.8 billion euros ($7 billion) cash. Abbott will make lump sum payment in the amount of 4.5 billion euros, and other 300 million euros will pay in 2011-2013 on reaching particular purposes. The transaction is the largest for Abbott since 2002.

The American company considers this transaction as the base for expansion of activity in emerging markets of the countries to Eastern Europe and Asia and also gets access to new medicines for treatment of hypertensia and Parkinson's disease. Besides, Abbott receives full control over the medicines Tricor and Trilipix concerning which Abbott and Solvay are marketing partners.

The range of Solvay Pharma includes also medicines of hormonal therapy. The company has also a small division on production of vaccines. This direction is very important against the background of spread of a virus of flu H1N1. At the beginning of September, 2009 the Belgian company announced the beginning of production of small batches of vaccine for clinical trials. Possibly, Abbott will be able to invest means in this business, however yet not clearly how fast the Solvay enterprises will be able to begin industrial production of vaccine.

According to analysts, Abbott it is necessary to reduce dependence on medicine for treatment of rheumatoid arthritis of Humira which sales volume in 2008 was $4.5 billion, or 15% of an indicator of net profit of the American company.

Abbott was succeeded "play" other applicant for Solvay Pharma acquisition – the Swiss Nycomed which was considered as the most probable buyer^[1].

Notes